Financial
Parent Fujifilm Holdings (4901.T) group FY2025 revenue ¥3.36tn (+5.0%); operating margin 10.4%; net income ¥276.7bn.
Group figures; Healthcare is one of several segments.
HQ Japan · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Parent Fujifilm Holdings (4901.T) group FY2025 revenue ¥3.36tn (+5.0%); operating margin 10.4%; net income ¥276.7bn.
Group figures; Healthcare is one of several segments.
Source: official results release · Year ended 2026-03-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | JP¥3.4tn | +5.0% | JP¥350.2bn | JP¥276.7bn | Fujifilm Holdings group |
Products not yet catalogued.
Parent Fujifilm Holdings (4901.T) group FY2025 revenue ¥3.36tn (+5.0%); operating margin 10.4%; net income ¥276.7bn.
Group figures; Healthcare is one of several segments.
No adverse media involving Fujifilm Healthcare found in HSH's search of the last 24 months.
Aug 2025: CISA published an advisory on a vulnerability in Fujifilm's Synapse Mobility image viewer that could allow access beyond role-based controls; Fujifilm released fixes (version 8.2 and patches) and workarounds. NHS DSPT status not yet checked.
Jul 2026: Fujifilm Healthcare Americas began a US Class 2 recall of Synapse PACS v7.4.310 because a software issue could make ruler measurements inaccurate (6 units).
No notable contract disputes, terminations or troubled implementations involving Fujifilm Healthcare found in HSH's search of the last 24 months.
No competitors linked yet.